Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Dose-escalation Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma

NCT05535673 is registered in ClinicalTrials.gov with Zhengzhou University as lead sponsor.

NCT NCT05535673
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05535673 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Dose-escalation Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Allogeneic CAR-T Targeting CD19 in Patients With Refractory or Relapsed B Cell Lymphoma
Lead sponsor
Zhengzhou University
Phase
Phase 1
Overall status
Unknown status
Start date
September 2, 2022
Completion date
July 1, 2025
Enrollment
15 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic, car-t, protein sequestration, non-gene edited, r/r b-nhl